FDA Approves Bulevirtide for Hepatitis Delta Virus
The FDA has approved bulevirtide, the first treatment for hepatitis delta virus infection in the US. This daily injection is intended for adults with chronic HDV infection, providing a new option for patients who previously had no FDA-approved therapies. The approval follows positive trial results and aims to improve management of a disease that can lead to serious liver complications.
- ▪Bulevirtide is the first FDA-approved treatment for hepatitis delta virus infection in the US.
- ▪The drug is administered as an 8.5-mg daily injection for adults with chronic HDV infection.
- ▪Clinical trials showed a significant increase in the rate of undetectable HDV RNA among participants treated with bulevirtide.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/fda-approves-bulevirtide-hepatitis-delta-virus-2026a1000h3x?src=rss |
| Publication time | Tue, 26 May 2026 02:16:37 EDT |
| Retrieval time | 2026-05-26T06:37:45.433Z |
| Last seen | 2026-05-26T06:37:45.433Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | CIsmMDU-9cHD |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The FDA approved bulevirtide (Hepcludex; Gilead Sciences), the first treatment for hepatitis delta virus (HDV) infection in the US.The 8.5-mg daily injection will treat adults with chronic HDV infection without cirrhosis or with compensated cirrhosis.The approval “fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available,” said Wendy Carter, DO, acting director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
